| ￥3300 | |
| Z04339-100 | |
|
|
|
|
|
|
|
|
|
| Species | Mouse | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 61.62 kDa | ||||
| Apparent Molecular Weight | Due to furin-like convertase cleavage site and glycosylation, the protein migrates to 32-42 kDa and 75-85 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Supplied as 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Concentration | Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford. | ||||
| Storage & Stability | This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles. |
| Target Background | Glypican-3 is a protein ,which is encoded by the GPC3 gene in humans.The protein core of GPC3 consists of two subunits, where the N-terminal subunit has a size of ~40 kDa and the C-terminal subunit is ~30 kDa.Glypican 3 is a potential therapeutic target for treating liver cancer and other cancers. Several therapeutic anti-GPC3 antibodies have been developed. |
| Synonyms | GPC3; DGSX; Glypican 3; GTR2-2; MXR7; OCI5; OCI-5; SGB; SGBS; SGBS1SDYS; SDYS; SGBS1 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
